Cancer stem cells in colorectal cancer from pathogenesis to therapy: Controversies and perspectives

被引:79
作者
Fanali, Caterina [1 ]
Lucchetti, Donatella [1 ]
Farina, Marisa [1 ]
Corbi, Maddalena [1 ]
Cufino, Valerio [1 ]
Cittadini, Achille [1 ]
Sgambato, Alessandro [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Ist Patol Gen, I-00168 Rome, Italy
关键词
Colorectal cancer; Cancer stem cells; Tumorigenesis; Cancer therapy; Prognostic marker; SHORTENED PATIENT SURVIVAL; METASTATIC COLON-CANCER; INHIBITS TUMOR-GROWTH; CD133; EXPRESSION; BETA-CATENIN; MONOCLONAL-ANTIBODY; ADHESION MOLECULE; MARKERS CD133; INTESTINAL EPITHELIUM; ADJUVANT THERAPY;
D O I
10.3748/wjg.v20.i4.923
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Colorectal cancer remains one of the most common and lethal malignancies worldwide despite the use of various therapeutic strategies. A better understanding of the mechanisms responsible for tumor initiation and progression is essential for the development of novel, more powerful therapies. The traditional, so-called "stochastic model" of tumor development, which assumes that each cancer cell is tumorigenic, has been deeply challenged during the past decade by the identification of cancer stem cells (CSCs), a biologically distinct subset of cells within the bulk of tumor mass. This discovery led to the development of the hierarchical model of tumorigenesis which assumes that only CSCs have the ability to initiate tumor growth, both at primary and metastatic sites. This model implies that the elimination of all CSCs is fundamental to eradicate tumors and that failure to do so might be responsible for the occurrence of relapses and/or metastases frequently observed in the clinical management of colorectal cancer patients. Identification and isolation of CSCs is essential for a better understanding of their role in the tumorigenetic process and for the development of CSC-specific therapies. Several methods have been used for this purpose and many efforts have been focused on the identification of specific CSC-surface markers. This review provides an overview of the proposed roles of CSC in human colorectal tumorigenesis focusing on the most important molecules identified as CSC-specific markers in colorectal cancer and on the potential strategies for the development of CSC-targeted therapy. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
引用
收藏
页码:923 / 942
页数:20
相关论文
共 132 条
  • [61] Mutations in the Ras-Raf Axis Underlie the Prognostic Value of CD133 in Colorectal Cancer
    Kemper, Kristel
    Versloot, Miranda
    Cameron, Katherine
    Colak, Selcuk
    de Sousa e Melo, Felipe
    de Jong, Joan H.
    Bleackley, Joanne
    Vermeulen, Louis
    Versteeg, Rogier
    Koster, Jan
    Medema, Jan Paul
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (11) : 3132 - 3141
  • [62] Immunohistochemical detection of CD133 expression in colorectal cancer: A clinicopathological study
    Kojima, Motohiro
    Ishii, Genichiro
    Atsumi, Naho
    Fujii, Satoshi
    Saito, Norio
    Ochiai, Atsushi
    [J]. CANCER SCIENCE, 2008, 99 (08): : 1578 - 1583
  • [63] Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC(-/-) colon carcinoma
    Korinek, V
    Barker, N
    Morin, PJ
    vanWichen, D
    deWeger, R
    Kinzler, KW
    Vogelstein, B
    Clevers, H
    [J]. SCIENCE, 1997, 275 (5307) : 1784 - 1787
  • [64] Kristiansen G, 2004, J MOL HISTOL, V35, P255
  • [65] A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers
    Langan, Russell C.
    Mullinax, John E.
    Ray, Satyajit
    Raiji, Manish T.
    Schaub, Nicholas
    Xin, Hong-Wu
    Koizumi, Tomotake
    Steinberg, Seth M.
    Anderson, Andrew
    Wiegand, Gordon
    Butcher, Donna
    Anver, Miriam
    Bilchik, Anton J.
    Stojadinovic, Alexander
    Rudloff, Udo
    Avital, Itzhak
    [J]. JOURNAL OF CANCER, 2012, 3 : 231 - 240
  • [66] MUC18, A MARKER OF TUMOR PROGRESSION IN HUMAN-MELANOMA, SHOWS SEQUENCE SIMILARITY TO THE NEURAL CELL-ADHESION MOLECULES OF THE IMMUNOGLOBULIN SUPERFAMILY
    LEHMANN, JM
    RIETHMULLER, G
    JOHNSON, JP
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (24) : 9891 - 9895
  • [67] Characterization of the Intestinal Cancer Stem Cell Marker CD166 in the Human and Mouse Gastrointestinal Tract
    Levin, Trevor G.
    Powell, Anne E.
    Davies, Paige S.
    Silk, Alain D.
    Dismuke, Adria D.
    Anderson, Eric C.
    Swain, John R.
    Wong, Melissa H.
    [J]. GASTROENTEROLOGY, 2010, 139 (06) : 2072 - U378
  • [68] Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer
    Lugli, A.
    Iezzi, G.
    Hostettler, I.
    Muraro, M. G.
    Mele, V.
    Tornillo, L.
    Carafa, V.
    Spagnoli, G.
    Terracciano, L.
    Zlobec, I.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 103 (03) : 382 - 390
  • [69] Regulation of CD133 by HDAC6 Promotes β-Catenin Signaling to Suppress Cancer Cell Differentiation
    Mak, Anthony B.
    Nixon, Allison M. L.
    Kittanakom, Saranya
    Stewart, Jocelyn M.
    Chen, Ginny I.
    Curak, Jasna
    Gingras, Anne-Claude
    Mazitschek, Ralph
    Neel, Benjamin G.
    Stagljar, Igor
    Moffat, Jason
    [J]. CELL REPORTS, 2012, 2 (04): : 951 - 963
  • [70] A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy
    Mao, Qin
    Zhang, Yu
    Fu, Xiaoyue
    Xue, Jianxin
    Guo, Wenhao
    Meng, Maobing
    Zhou, Zongguang
    Mo, Xianming
    Lu, You
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (02) : 211 - 222